Human LIMCH1 knockout HeLa cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
- Sanger seq
Unknown
Sanger Sequencing - Human LIMCH1 knockout HeLa cell lysate (AB263245)
Allele-1 : 8 bp deletion in exon 8
- Sanger seq
Unknown
Sanger Sequencing - Human LIMCH1 knockout HeLa cell lysate (AB263245)
Allele-2 : 2 bp deletion in exon 8
Complementary Products
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LIMCH1 modulates cytoskeletal dynamics and plays a role in cell shape and motility. It forms part of protein complexes that regulate the architecture of the actin cytoskeleton. These complexes involve other actin-binding proteins contributing to processes like cell adhesion and migration. LIMCH1 influences the remodeling of cytoskeletal structures critical for cellular responses to environmental changes and mechanical stress.
Pathways
Researchers identify LIMCH1 as a component in the RhoA signaling pathway which controls actin cytoskeleton dynamics. LIMCH1 interacts with proteins like Rho-associated protein kinase (ROCK) and myosin light chain kinase (MLCK) coordinating actomyosin contractility. Another significant pathway involving LIMCH1 is the regulation of focal adhesion where it associates with vinculin and talin contributing to the linkage between the plasma membrane and the cytoskeletal framework.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com